Verastem (VSTM)

• Market cap: $186M
• 1 day: -5.63%
• 5 days: -8.91%
• 1 month: 10.55%
• 3 months: 45.49%
• 6 months: 28.92%
• Year to date: -49.52%
• 1 year: -46.07%
• 5 years: -73.75%
• 10 years: -95.84%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Employees: 73

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

338% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 8

76% more capital invested

Capital invested by funds: $45.2M [Q2] → $79.5M (+$34.3M) [Q3]

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

12% more funds holding

Funds holding: 67 [Q2] → 75 (+8) [Q3]

6.3% more ownership

Funds ownership: 59.78% [Q2] → 66.08% (+6.3%) [Q3]

6% less call options, than puts

Call options by funds: $137K | Put options by funds: $145K

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 67% upside
• Avg. target: $10.50 151% upside
• High target: $13 210% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Mizuho Mara Goldstein 50% 1-year accuracy 2 / 4 met price target	115% upside $9	Outperform Maintained	19 Dec 2024
HC Wainwright & Co. Sean Lee 60% 1-year accuracy 12 / 20 met price target	67% upside $7	Buy Reiterated	19 Dec 2024
RBC Capital Gregory Renza 40% 1-year accuracy 32 / 81 met price target	210% upside $13	Outperform Reiterated	18 Oct 2024
Guggenheim Michael Schmidt 26% 1-year accuracy 5 / 19 met price target	210% upside $13	Buy Initiated	30 Sept 2024